-
Electronic (PDF)
-
Site License
-
Enterprisewide
Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, December 2011, Pages: 73
Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Thalassemia Therapeutics market. The report identifies the key trends shaping and driving the global Thalassemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Thalassemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Thalassemia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Thalassemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Thalassemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Thalassemia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Thalassemia Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Thalassemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Thalassemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Thalassemia Therapeutics market landscape? – Identify, understand and capitalize.
1
1
1.1 List of Tables
1.2 List of Figures
2 Thalassemia Therapeutics - Introduction
2.1 Overview
2.1.1 Alpha Thalassemia
2.1.2 Beta Thalassemia
2.2 Etiology
2.2.1 Alpha Thalassemia
2.2.2 Beta Thalassemia
2.3 Epidemiology
2.4 Signs and Symptoms of Alpha and Beta Thalassemias
2.4.1 Alpha thalassemia
2.4.2 Beta thalassemia
2.5 Diagnosis
2.5.1 Alpha thalassemia
2.5.2 Beta Thalassemia
2.6 Treatment and Management Pattern of Alpha and Beta Thalassemias
2.6.1 Blood Transfusion
2.6.2 Iron Chelation Therapy
2.6.3 Splenectomy
2.6.4 Allogeneic hematopoietic transplantation
2.7 GlobalData Pipeline Report Guidance
3 Thalassemia Therapeutics - Market Characterization
3.1 Thalassemia Therapeutics Market Size (2005-2010) - Global
3.2 Thalassemia Therapeutics Market Forecast (2010-2018) - Global
3.3 Thalassemia Therapeutics Market Size (2005-2010) - The US
3.4 Thalassemia Therapeutics Market Forecast (2010-2018) - The US
3.5 Thalassemia Therapeutics Market Size (2005-2010) - The UK
3.6 Thalassemia Therapeutics Market Forecast (2010-2018) - The UK
3.7 Thalassemia Therapeutics Market Size (2005-2010) - France
3.8 Thalassemia Therapeutics Market Forecast (2010-2018) - France
3.9 Thalassemia Therapeutics Market Size (2005-2010) - Germany
3.10 Thalassemia Therapeutics Market Forecast (2010-2018) - Germany
3.11 Thalassemia Therapeutics Market Size (2005-2010) - Italy
3.12 Thalassemia Therapeutics Market Forecast (2010-2018) - Italy
3.13 Thalassemia Therapeutics Market Size (2005-2010) - Spain
3.14 Thalassemia Therapeutics Market Forecast (2010-2018) - Spain
3.15 Thalassemia Therapeutics Market Size (2005-2010) - Japan
3.16 Thalassemia Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Thalassemia Therapeutics Market
3.17.1 Drivers for the Thalassemia Therapeutics Market
3.17.2 Barriers for the Thalassemia Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 Thalassemia Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Thalassemia Therapeutics Market
4.3.1 Desferal (deferoxamine mesylate)
4.3.2 Exjade (deferasirox)
4.3.3 Ferriprox (deferiprone)
4.4 Key Takeaway
5 Thalassemia Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Thalassemia Pipeline - Pipeline by Phases of Development
5.3.1 Thalassemia Therapeutics - Phase II Pipeline
5.3.2 Thalassemia Therapeutics - Phase I/II Pipeline
5.3.3 Thalassemia Therapeutics - Preclinical Pipeline
5.3.4 Thalassemia Therapeutics - Discovery Pipeline
5.4 Thalassemia Therapeutics - Pipeline by Mechanism of Action
5.4.1 Technology Trends Analytic Framework
5.5 Molecule Profile for Drugs under Phase II Clinical Development
5.5.1 FBS0701
5.5.2 HQK-1001
5.5.3 Exjade
5.6 Key Takeaway
6 Thalassemia Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Thalassemia Therapeutics Clinical Trials
7 Thalassemia Therapeutics - Strategic Assessment
7.1 Thalassemia Therapeutics: Implications for Future Market Competition
8 Thalassemia Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Novartis Pharmaceuticals
8.2.2 HemaQuest Pharmaceuticals Inc.
8.2.3 FerroKin BioSciences Inc.
8.3 Other Companies in the Thalassemia Therapeutics Market, 2011
9 Thalassemia Therapeutics - Licensing and Partnership Deals
10 Thalassemia Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Thalassemia Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 2: Thalassemia Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 3: Thalassemia Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 4: Thalassemia Therapeutics Market, The US, Revenue ($m), 2010-2018
Table 5: Thalassemia Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 6: Thalassemia Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 7: Thalassemia Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: Thalassemia Therapeutics Market, France, Forecast ($m), 2010-2018
Table 9: Thalassemia Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: Thalassemia Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 11: Thalassemia Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: Thalassemia Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 13: Thalassemia Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: Thalassemia Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 15: Thalassemia Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 16: Thalassemia Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 17: Thalassemia Therapeutics - Phase II Pipeline, 2011
Table 18: Thalassemia Therapeutics - Phase I/II Pipeline, 2011
Table 19: Thalassemia Therapeutics - Preclinical Pipeline, 2011
Table 20: Thalassemia Therapeutics - Discovery Pipeline, 2011
Table 21: Thalassemia Therapeutics - Clinical Trials by Country, 2011
Table 22: Thalassemia Therapeutics - Clinical Trials by Phase, 2011
Table 23: Thalassemia Therapeutics - Clinical Trials by Status, 2011
Table 24: Thalassemia Therapeutics - Clinical Trials by Overall Sponsors, 2011
Table 25: Thalassemia Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Table 26: Thalassemia Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 27: Novartis - Thalassemia Pipeline, 2011
Table 28: HemaQuest Pharmaceuticals - Thalassemia Pipeline, 2011
Table 29: FerroKin BioSciences - Thalassemia Pipeline, 2011
Table 30: Thalassemia Therapeutics - Future Players, 2011
Table 31: Thalassemia Therapeutics, Global, Deals
1.2 List of Figures
Figure 1: Thalassemia Therapeutics - Diseased Cells
Figure 2: Thalassemia Therapeutics - Inheritance Pattern of Alpha Thalassemia
Figure 3: Thalassemia Therapeutics - Inheritance Pattern of Alpha Thalassemia
Figure 4: Thalassemia Therapeutics - Inheritance Pattern of Alpha Thalassemia
Figure 5: Thalassemia Therapeutics - Inheritance Pattern of Alpha Thalassemia
Figure 6: Thalassemia Therapeutics - Inheritance Pattern of Beta Thalassemia
Figure 7: Thalassemia Therapeutics - Inheritance Pattern of Beta Thalassemia
Figure 8: Thalassemia Therapeutics - Inheritance Pattern of Beta Thalassemia
Figure 9: Thalassemia Therapeutics - Inheritance Pattern of Beta Thalassemia
Figure 10: Thalassemia Therapeutics - Diagnostic Workup
Figure 11: Thalassemia Therapeutics - Treatment with Iron Chelation Therapy for Iron Overload
Figure 12: Thalassemia Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 13: Thalassemia Therapeutics, Market Share ($m), 2010
Figure 14: Thalassemia Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 15: Thalassemia Therapeutics, Market Share ($m), 2018
Figure 16: Thalassemia Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 17: Thalassemia Therapeutics Market, The US, Forecast ($m), 2010-2018
Figure 18: Thalassemia Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 19: Thalassemia Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 20: Thalassemia Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 21: Thalassemia Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 22: Thalassemia Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 23: Thalassemia Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 24: Thalassemia Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 25: Thalassemia Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 26: Thalassemia Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 27: Thalassemia Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 28: Thalassemia Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 29: Thalassemia Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 30: Thalassemia Therapeutics Market, Drivers and Barriers, 2011
Figure 31: Opportunity and Unmet Need in the Thalassemia Therapeutics Market, 2011
Figure 32: Thalassemia Therapeutics Market - Strategic Competitor Assessment, 2011
Figure 33: Thalassemia - Pipeline by Phase (% share), 2011
Figure 34: Thalassemia - Pipeline by Phase of Development, 2011
Figure 35: Thalassemia Therapeutics - Clinical Pipeline by Mechanism of Action
Figure 36: Thalassemia Therapeutics - Technology Trends Analytics Framework, 2011
Figure 37: Thalassemia Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 38: Thalassemia Therapeutics - Clinical Trials by Country, 2011
Figure 39: Thalassemia Therapeutics - Clinical Trials by Phase, 2011
Figure 40: Thalassemia Therapeutics - Clinical Trials by Status, 2011
Figure 41: Thalassemia Therapeutics - Clinical Trials by Overall Sponsors, 2011
Figure 42: Thalassemia Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Figure 43: Thalassemia Therapeutics - Top Companies Participating in Therapeutic Clinical Trials, 2011
Figure 44: Implications for Future Market Competition in Thalassemia Therapeutic Market, 2011
Figure 45: Thalassemia Therapeutics - Pipeline by Company, 2011
Figure 46: GlobalData Market Forecasting Model
GlobalData, the industry analysis specialist, has released its new report, “Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Thalassemia Therapeutics market. The report identifies the key trends shaping and driving the global Thalassemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Thalassemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The Thalasssemia Therapeutics Market is Forecast to Grow Up Until 2018
GlobalData’s analysis estimated the thalassemia therapeutics market to be worth $535.5m in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.0% for the next eight years, reaching $991.6m by 2018. The growth is attributed to increasing prevalence of thalassemia, which leads to an increase in the drug-treated population. The recent launch of Ferriprox in October 2011 in the US, and the expected launches of Exjade, FBS0701 and HQK-1001 towards the latter part of the forecast period in the US (2017) and the EU (2018) are expected to further contribute towards the growth of the thalassemia therapeutics market.
Thalassemia Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018
Sources: GlobalData, Centers for Disease Control and Prevention (CDC); National Health Service (NHS); Kinderklinik A, Haemoglobinopathies and newborn haemoglobinopathy screening in Germany. J Clin Pathol. 2009 Jan;62(1):34; Pereira MM et al., Molecular heterogeneity of beta-thalassemia alleles in Spain and its importance in the diagnosis and prevention of beta-thalassemia major and sickle cell disorders. Hemoglobin. 2009;33(3):226-34; Hattori, Thalassemia mutations and their clinical aspects in Japan., Int J Hematol. 2002 Aug;76 Suppl 2:90-2; GlobalData Epidemiology-based Market Forecasting Model; Primary Research Interviews; KOL Interviews
Unmet Need Expected to Remain Unchanged Over the Next Few Years
GlobalData has estimated the thalassemia therapeutics market has significant unmet need. The currently marketed drugs - iron chelating drugs that are used to treat iron overload arising from blood transfusions - do meet patient needs to a satisfactory extent. However, there is no cure for the disease through the drugs that are currently available and this remains a significant unmet need in the thalassemia therapeutics market. The need for safer and more efficacious drugs is also another unmet need. Also, the cumbersome routes of administration and dosing regimens have a negative effect on clinical outcomes.With no new molecule expected to hit the market until almost the end of the forecast period, the clinical unmet need is likely to remain unaltered over the next few years.
Novartis Pharmaceuticals
HemaQuest Pharmaceuticals Inc.
FerroKin BioSciences Inc.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
